PLX
Protalix Biotherapeutics Inc
2.80$
-1.4%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -193.1% | -556.5% | -348.9% | -47.4% | -22.6% | -35.4% | -41.5% | -26.8% | -52.5% | -2.0% | 16.2% | -22.7% | |
| 20.7% | 54.3% | 21.6% | 9.1% | 4.9% | 3.0% | 2.1% | 2.9% | 2.3% | 1.8% | 2.4% | 2.8% | |
| 8.2% | 41.3% | 10.7% | 1.6% | 1.5% | 1.5% | 5.0% | 6.2% | 4.4% | 5.3% | 6.1% | 4.4% | |
| 3.1% | 79.5% | -69.6% | 198.9% | 1.5% | 1.5% | 4.4% | 9.4% | 1.2% | – | – | – | |
| -37.8% | -75.7% | 12.1% | 138.1% | 39.5% | -12.5% | -43.1% | 25.8% | -25.2% | -16.1% | 1.5% | -19.1% | |
| 5.2% | 10.6% | 9.2% | 4.6% | 2.0% | 1.1% | 1.0% | 3.8% | 1.3% | 1.8% | 2.4% | 3.1% | |
| -6.6% | 902.5% | -10.5% | -5.3% | -1.7% | -1.6% | -31.7% | 49.3% | -10.6% | -25.5% | 7.9% | -4.5% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.3% | 12.2% | 0.2% | 0.0% | – | – | 74.2% | 120.5% | 17.3% | 37.7% | 6.8% | 17.7% | |
| 129.8% | 451.0% | 213.9% | -6.7% | -13.9% | -0.4% | -0.3% | -89.0% | 0.0% | 0.0% | -38.2% | 0.0% | |
| 0.3% | 152.0% | 214.1% | -6.7% | -13.9% | 85.0% | 73.9% | 31.5% | 17.3% | 37.7% | -31.5% | 17.7% | |
| -208.6% | 495.1% | -142.3% | -57.5% | -39.0% | -36.6% | 0.8% | 54.0% | -45.9% | 10.0% | -7.3% | -8.3% | |
| -198.3% | -567.1% | -358.2% | -52.0% | -24.6% | -36.5% | -42.5% | -30.6% | -53.8% | -3.8% | 13.8% | -25.8% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.